Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £315.15B | 27.5x | 1.31 | GBX 6,881.40 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie Inc | London | Healthcare | Pharmaceuticals | £289.38B | 87.3x | -7.5 | GBX 17,734.36 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £214.24B | 31x | -1.03 | GBX 26,667.30 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £214.24B | 31x | -1.04 | GBX 28,339.24 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £184.58B | 33.8x | 1.83 | GBX 12,064 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.7% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £184.39B | 13.8x | 0 | GBX 7,377.78 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £172.50B | 18.9x | -1.03 | GBX 8,733.82 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £111.71B | 23.7x | 8.09 | GBX 9,033.28 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £111.64B | 296.2x | -3.23 | GBX 9,044.84 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £60.34B | 23.9x | -0.48 | GBX 1,509 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £49.83B | 21.7x | -3.13 | GBX 11,105.48 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £37.18B | 24.4x | 0.64 | GBX 414.90 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.6% Downside | Upgrade to Pro+ | |
UCB L | London | Healthcare | Pharmaceuticals | £30.22B | 34.6x | 0.15 | GBX 16,013.40 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £19.51B | -26.5x | -0.33 | GBX 1,958.04 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £16.49B | 12.7x | 0.31 | GBX 11,352.36 | 100,000% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £15.33B | -2,379.2x | 23.64 | GBX 3,494.76 | 38.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £9.30B | 26.6x | GBX 4,502.58 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £8.22B | 28x | 0.54 | GBX 2,380.80 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.65B | 27.1x | -0.56 | GBX 9,339.36 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £6.32B | 23.6x | 0.44 | GBX 4,579.51 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | £5.58B | 46.6x | 0.15 | GBX 890.92 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | London | Healthcare | Pharmaceuticals | £5.58B | 46.6x | 0.15 | GBX 649.37 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £4.83B | 21.4x | 0.19 | GBX 2,158 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
H Lundbeck L | London | Healthcare | Pharmaceuticals | £4.23B | 13.3x | 0.32 | GBX 437.19 | -77.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £4.11B | 8.1x | 0.03 | GBX 2,229.47 | 114.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £3.70B | 40.6x | 0.6 | GBX 1,657.77 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | £2.94B | 85.8x | -22.76 | GBX 4,744.45 | 22.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | £2.47B | 37.2x | -2.97 | GBX 17,910.54 | -10% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | £2.15B | -64.9x | 7.69 | GBX 251 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | £2.10B | 17.7x | 0.93 | GBX 24,692.63 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Almirall | London | Healthcare | Pharmaceuticals | £1.75B | 203.5x | 1.67 | GBX 809.02 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharma Mar | London | Healthcare | Pharmaceuticals | £1.44B | -927x | GBX 7,588.13 | -8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Fagron NV | London | Healthcare | Pharmaceuticals | £1.11B | 16.6x | 1.21 | GBX 1,528.71 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cosmo Pharmas | London | Healthcare | Pharmaceuticals | £939.93M | 15.9x | 0.03 | GBX 5,834.58 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogaia AB | London | Healthcare | Pharmaceuticals | £935.40M | 35.2x | -9.17 | GBX 912.37 | -76.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Indivior | London | Healthcare | Pharmaceuticals | £935.37M | -420.8x | 0.01 | GBX 722.50 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faes Farma | London | Healthcare | Pharmaceuticals | £867.21M | 10.8x | GBX 278.77 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Uniphar | London | Healthcare | Pharmaceuticals | £597.29M | 15.9x | 0.26 | GBX 213 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medincell | London | Healthcare | Pharmaceuticals | £395.55M | -13.1x | 1.67 | GBX 1,197.82 | 65.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alliance Pharma | London | Healthcare | Pharmaceuticals | £335.15M | -10x | 0.68 | GBX 62 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.7% Upside | Upgrade to Pro+ | |
Niox PLC | London | Healthcare | Pharmaceuticals | £268.24M | 23.6x | 1.92 | GBX 66.40 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.6% Upside | Upgrade to Pro+ | |
Beximco Pharma. | London | Healthcare | Pharmaceuticals | £225.63M | 5.6x | 0.19 | GBX 38.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Santhera Pharmas Holding | London | Healthcare | Pharmaceuticals | £178.59M | 2.7x | 0.02 | GBX 1,388.99 | 62.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Animalcare | London | Healthcare | Pharmaceuticals | £157.29M | 7.4x | 0.02 | GBX 227 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.3% Upside | Upgrade to Pro+ | |
Photocure | London | Healthcare | Pharmaceuticals | £100.92M | 96.8x | 0.49 | GBX 365.57 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Venture Life Group | London | Healthcare | Pharmaceuticals | £51.54M | 68.4x | 0.37 | GBX 41 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eco Animal | London | Healthcare | Pharmaceuticals | £40.66M | 58.1x | 0.44 | GBX 60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kala Pharmaceuticals | London | Healthcare | Pharmaceuticals | £32.36M | -0.6x | -0.02 | GBX 520.37 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
bluebird bio | London | Healthcare | Pharmaceuticals | £31.99M | -0.1x | 0 | GBX 646.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRUSHMETRIC | Aquis Exchange | Healthcare | Pharmaceuticals | £30.16M | -4.4x | GBX 12.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |